Nov 14, 2023 / 08:30AM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
All right. Good morning, everybody. Thank you for joining us here on a beautiful morning session here at the Jefferies Global Healthcare Conference here in London. I am Michael Yee, one of the senior biotechnology analyst here at Jefferies. And I'm really excited to have Stuart Arbuckle, Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals.
I started -- before we jumped on the stage here and I said the amazing thing here about having Vertex is we have a biotech at an all-time high. So that is a great thing here given how challenging it is in the biotech sector. So it is refreshing to have Vertex up here with us. And part of that is because there are so many things going on. So hopefully, we can hit on some of the key topics in just 25 minutes.
Stu, maybe if I turn it over to you, the first thing I would just ask you is to give us a very brief snapshot of some of the things that you're excited about for 2024, obviously, with CF with -- I know people will want to talk briefly about pain. And
Vertex Pharmaceuticals Inc at Jefferies London Healthcare Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers